Cargando…
Determinants of Use of Intermittent Preventive Treatment of Malaria in Pregnancy: Jinja, Uganda
BACKGROUND: Maternal malaria is associated with serious adverse pregnancy outcomes. One recommended means of preventing malaria during pregnancy is intermittent preventive therapy (IPTp) with sulfadoxine/pyrimethamine (SP). We sought to identify determinants of preventive use of SP during pregnancy...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993958/ https://www.ncbi.nlm.nih.gov/pubmed/21124732 http://dx.doi.org/10.1371/journal.pone.0015066 |
_version_ | 1782192867831185408 |
---|---|
author | Sangaré, Laura R. Stergachis, Andy Brentlinger, Paula E. Richardson, Barbra A. Staedke, Sarah G. Kiwuwa, Mpungu S. Weiss, Noel S. |
author_facet | Sangaré, Laura R. Stergachis, Andy Brentlinger, Paula E. Richardson, Barbra A. Staedke, Sarah G. Kiwuwa, Mpungu S. Weiss, Noel S. |
author_sort | Sangaré, Laura R. |
collection | PubMed |
description | BACKGROUND: Maternal malaria is associated with serious adverse pregnancy outcomes. One recommended means of preventing malaria during pregnancy is intermittent preventive therapy (IPTp) with sulfadoxine/pyrimethamine (SP). We sought to identify determinants of preventive use of SP during pregnancy among recently pregnant women in Uganda. Additionally, we characterized the timing of and indications for the administration of SP at antenatal care (ANC) visits and missed opportunities for SP administration. METHODOLOGY/PRINCIPAL FINDINGS: Utilizing a population-based random sample, we interviewed 500 women living in Jinja, Uganda who had been pregnant in the past year. Thirty-eight percent (192/500) of women received SP for the treatment of malaria and were excluded from the analysis of IPTp-SP. Of the remaining women, 275 (89.3%) reported at least two ANC visits after the first trimester and had an opportunity to receive IPTp-SP according to the Ugandan guidelines, but only 86 (31.3%) of these women received a full two-dose course of IPTp. The remaining 189 (68.7%) women missed one or more doses of IPTp-SP. Among the 168 women that were offered IPTp, 164 (97.6%) of them took the dose of SP. CONCLUSIONS/SIGNIFICANCE: Use of IPTp in Uganda was found to be far below target levels. Our results suggest that women will take SP for IPTp if it is offered during an ANC visit. Missed opportunities to administer IPTp-SP during ANC were common in our study, suggesting provider-level improvements are needed. |
format | Text |
id | pubmed-2993958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-29939582010-12-01 Determinants of Use of Intermittent Preventive Treatment of Malaria in Pregnancy: Jinja, Uganda Sangaré, Laura R. Stergachis, Andy Brentlinger, Paula E. Richardson, Barbra A. Staedke, Sarah G. Kiwuwa, Mpungu S. Weiss, Noel S. PLoS One Research Article BACKGROUND: Maternal malaria is associated with serious adverse pregnancy outcomes. One recommended means of preventing malaria during pregnancy is intermittent preventive therapy (IPTp) with sulfadoxine/pyrimethamine (SP). We sought to identify determinants of preventive use of SP during pregnancy among recently pregnant women in Uganda. Additionally, we characterized the timing of and indications for the administration of SP at antenatal care (ANC) visits and missed opportunities for SP administration. METHODOLOGY/PRINCIPAL FINDINGS: Utilizing a population-based random sample, we interviewed 500 women living in Jinja, Uganda who had been pregnant in the past year. Thirty-eight percent (192/500) of women received SP for the treatment of malaria and were excluded from the analysis of IPTp-SP. Of the remaining women, 275 (89.3%) reported at least two ANC visits after the first trimester and had an opportunity to receive IPTp-SP according to the Ugandan guidelines, but only 86 (31.3%) of these women received a full two-dose course of IPTp. The remaining 189 (68.7%) women missed one or more doses of IPTp-SP. Among the 168 women that were offered IPTp, 164 (97.6%) of them took the dose of SP. CONCLUSIONS/SIGNIFICANCE: Use of IPTp in Uganda was found to be far below target levels. Our results suggest that women will take SP for IPTp if it is offered during an ANC visit. Missed opportunities to administer IPTp-SP during ANC were common in our study, suggesting provider-level improvements are needed. Public Library of Science 2010-11-29 /pmc/articles/PMC2993958/ /pubmed/21124732 http://dx.doi.org/10.1371/journal.pone.0015066 Text en Sangaré et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Sangaré, Laura R. Stergachis, Andy Brentlinger, Paula E. Richardson, Barbra A. Staedke, Sarah G. Kiwuwa, Mpungu S. Weiss, Noel S. Determinants of Use of Intermittent Preventive Treatment of Malaria in Pregnancy: Jinja, Uganda |
title | Determinants of Use of Intermittent Preventive Treatment of Malaria in Pregnancy: Jinja, Uganda |
title_full | Determinants of Use of Intermittent Preventive Treatment of Malaria in Pregnancy: Jinja, Uganda |
title_fullStr | Determinants of Use of Intermittent Preventive Treatment of Malaria in Pregnancy: Jinja, Uganda |
title_full_unstemmed | Determinants of Use of Intermittent Preventive Treatment of Malaria in Pregnancy: Jinja, Uganda |
title_short | Determinants of Use of Intermittent Preventive Treatment of Malaria in Pregnancy: Jinja, Uganda |
title_sort | determinants of use of intermittent preventive treatment of malaria in pregnancy: jinja, uganda |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993958/ https://www.ncbi.nlm.nih.gov/pubmed/21124732 http://dx.doi.org/10.1371/journal.pone.0015066 |
work_keys_str_mv | AT sangarelaurar determinantsofuseofintermittentpreventivetreatmentofmalariainpregnancyjinjauganda AT stergachisandy determinantsofuseofintermittentpreventivetreatmentofmalariainpregnancyjinjauganda AT brentlingerpaulae determinantsofuseofintermittentpreventivetreatmentofmalariainpregnancyjinjauganda AT richardsonbarbraa determinantsofuseofintermittentpreventivetreatmentofmalariainpregnancyjinjauganda AT staedkesarahg determinantsofuseofintermittentpreventivetreatmentofmalariainpregnancyjinjauganda AT kiwuwampungus determinantsofuseofintermittentpreventivetreatmentofmalariainpregnancyjinjauganda AT weissnoels determinantsofuseofintermittentpreventivetreatmentofmalariainpregnancyjinjauganda |